Impact of Pathological Lymphovascular Invasion of Lung Adenocarcinoma after Induction Chemoradiotherapy.
We investigated the clinical significance of lymphovascular invasion (LVI) in locally advanced lung adenocarcinoma after induction chemoradiotherapy (CRT).
We retrospectively reviewed patients with completely resected lung adenocarcinoma after induction CRT from 2007 to 2021 at our institution. We evaluated the effects of LVI on recurrence-free survival (RFS) and overall survival (OS).
Fifty-six patients were included. The reasons for induction CRT were superior sulcus tumor (n = 11, 19.6%), direct invasion of other organs (n = 7, 12.5%), bulky N1 (n = 3, 5.4%), and N2 (n = 35, 62.5%). A pathological complete response was observed in 6 patients (10.7%). LVI was present in 14 patients (25.0%) and absent in 42 (75.0%). The LVI-positive group had significantly worse 5-year RFS (7.8% vs. 49.7%, p <0.001) and OS (35.2% vs. 73.5%, p = 0.003) than the LVI-negative group. Multivariate analysis revealed that LVI was a significant prognostic factor for both RFS (hazard ratio [HR], 3.91; 95% confidence interval [CI], 1.64-9.32, p = 0.002) and OS (HR, 5.75; 95% CI, 1.92-17.20, p = 0.002).
LVI can be a poor prognostic factor and an important biomarker for assessing the effectiveness of multimodal treatment in lung adenocarcinoma.
We retrospectively reviewed patients with completely resected lung adenocarcinoma after induction CRT from 2007 to 2021 at our institution. We evaluated the effects of LVI on recurrence-free survival (RFS) and overall survival (OS).
Fifty-six patients were included. The reasons for induction CRT were superior sulcus tumor (n = 11, 19.6%), direct invasion of other organs (n = 7, 12.5%), bulky N1 (n = 3, 5.4%), and N2 (n = 35, 62.5%). A pathological complete response was observed in 6 patients (10.7%). LVI was present in 14 patients (25.0%) and absent in 42 (75.0%). The LVI-positive group had significantly worse 5-year RFS (7.8% vs. 49.7%, p <0.001) and OS (35.2% vs. 73.5%, p = 0.003) than the LVI-negative group. Multivariate analysis revealed that LVI was a significant prognostic factor for both RFS (hazard ratio [HR], 3.91; 95% confidence interval [CI], 1.64-9.32, p = 0.002) and OS (HR, 5.75; 95% CI, 1.92-17.20, p = 0.002).
LVI can be a poor prognostic factor and an important biomarker for assessing the effectiveness of multimodal treatment in lung adenocarcinoma.
Authors
Kabuto Kabuto, Menju Menju, Nishikawa Nishikawa, Terada Terada, Yoshizawa Yoshizawa, Date Date
View on Pubmed